Compare Allstate Corp (ALL) vs Novartis AG (NVS) Price & Performance

Allstate (ALL) trades at $256.24, down 4.98% on the day, but remains near recent highs with strong technical support at $253. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, driven by improved underwriting and investment income. Revenue growth has accelerated from $51.4B in 2022 to $67.1B in 2025, with net income margin expanding to 19.19%. Analyst consensus is a Buy with a $266.47 price target, though sentiment is mixed on sustainability of peak profitability.

Outlook is positive given earnings momentum and attractive valuation (P/E 5.25), but risks include potential normalization of underwriting margins and macroeconomic sensitivity. The stock offers value with high ROE (49.11%) and consistent dividend payments, yet investors should weigh cyclical insurance pressures against fundamental strength.

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.